Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by VITRAC Therapeutics, LLC

VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor, VIC-1911, and G12C Inhibitor, Sotorasib, for KRAS G12C-Mutant Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
From VITRAC Therapeutics, LLC
Via Business Wire
VITRAC Therapeutics Initiates a Phase 1 Clinical Trial with the Aurora Kinase A Inhibitor VIC-1911 and G12C Inhibitor Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
From VITRAC Therapeutics, LLC
Via Business Wire
VITRAC Therapeutics Initiates a Phase 1/2 Clinical Trial with the Aurora Kinase A inhibitor VIC-1911 in GVHD Prophylaxis
From VITRAC Therapeutics, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.